Tdam USA Inc. lowered its stake in Amgen, Inc. (NASDAQ:AMGN) by 6.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,663 shares of the medical research company’s stock after selling 780 shares during the period. Tdam USA Inc.’s holdings in Amgen were worth $2,149,000 at the end of the most recent reporting period.
A number of other large investors also recently added to or reduced their stakes in AMGN. Norges Bank bought a new stake in Amgen in the fourth quarter valued at $1,283,248,000. Thoroughbred Financial Services LLC boosted its holdings in Amgen by 19,447.3% in the second quarter. Thoroughbred Financial Services LLC now owns 1,805,392 shares of the medical research company’s stock valued at $180,539,000 after acquiring an additional 1,796,156 shares in the last quarter. Ellis Investment Partners LLC boosted its holdings in Amgen by 18,906.7% in the first quarter. Ellis Investment Partners LLC now owns 605,934 shares of the medical research company’s stock valued at $605,000 after acquiring an additional 602,746 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Amgen by 5.8% in the fourth quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock valued at $1,720,250,000 after acquiring an additional 482,760 shares in the last quarter. Finally, First Trust Advisors LP boosted its holdings in Amgen by 37.3% in the second quarter. First Trust Advisors LP now owns 1,196,708 shares of the medical research company’s stock valued at $220,529,000 after acquiring an additional 325,404 shares in the last quarter. Institutional investors and hedge funds own 78.96% of the company’s stock.
A number of analysts have recently commented on AMGN shares. JPMorgan Chase & Co. restated a “hold” rating on shares of Amgen in a report on Friday, August 9th. BidaskClub upgraded shares of Amgen from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Morgan Stanley dropped their target price on shares of Amgen from $211.00 to $207.00 and set an “overweight” rating on the stock in a report on Monday, July 15th. Cowen restated a “buy” rating and set a $229.00 target price on shares of Amgen in a report on Wednesday, May 1st. Finally, Royal Bank of Canada restated a “hold” rating on shares of Amgen in a report on Sunday. Nine equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Amgen has a consensus rating of “Buy” and a consensus price target of $211.78.
In related news, Director R Sanders Williams sold 425 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total value of $77,792.00. Following the transaction, the director now owns 16,336 shares in the company, valued at approximately $2,990,141.44. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $175.68, for a total transaction of $351,360.00. Following the completion of the transaction, the director now owns 16,219 shares in the company, valued at approximately $2,849,353.92. The disclosure for this sale can be found here. In the last quarter, insiders sold 4,425 shares of company stock worth $804,312. 0.25% of the stock is currently owned by company insiders.
Shares of AMGN stock traded down $4.40 during mid-day trading on Wednesday, reaching $201.38. 1,310,837 shares of the company’s stock traded hands, compared to its average volume of 3,052,886. The firm has a market cap of $117.69 billion, a P/E ratio of 13.98, a P/E/G ratio of 2.30 and a beta of 1.19. The firm’s 50-day simple moving average is $182.89. Amgen, Inc. has a 12 month low of $166.30 and a 12 month high of $211.90. The company has a current ratio of 2.89, a quick ratio of 2.60 and a debt-to-equity ratio of 2.58.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, July 30th. The medical research company reported $3.97 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.58 by $0.39. The company had revenue of $5.87 billion for the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a net margin of 33.78% and a return on equity of 76.17%. Amgen’s revenue was down 3.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.83 EPS. On average, sell-side analysts expect that Amgen, Inc. will post 14.23 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 6th. Investors of record on Thursday, August 15th will be paid a $1.45 dividend. This represents a $5.80 dividend on an annualized basis and a yield of 2.88%. The ex-dividend date of this dividend is Wednesday, August 14th. Amgen’s payout ratio is 40.28%.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Read More: What is meant by holder of record?
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.